Strategies for Empiric Therapy in HABP/VABP
Key Aspects of Antimicrobial Resistance in HABP/VABP
Strategies for Effective Antimicrobial Resistance Risk Stratification
Question and Answer Session
Date / Time
Marion Elligsen, BScPhm, RPh
Sunnybrook Research Institute
Antimicrobial Stewardship Pharmacy Lead
Department of Pharmacy
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Keith S. Kaye, MD, MPH
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey
Andrew Shorr, MD, MPH, MBA
Director, Pulmonary and Critical Care Medicine
The goal of this activity is to improve learners’ knowledge, competence, and performance in applying the latest practice guidance and data to provide appropriately broad empiric regimens for HABP/VABP in patients with risk factors for antimicrobial resistance.
This program is intended for physicians, pharmacists, and other healthcare professionals who care for patients with HABP and VABP.
Upon completion of this activity, participants should be able to:
Stratify patients with HABP/VABP who are at risk for XDROs based on local resistance patterns and patient-specific factors
Apply appropriate use of broad-spectrum antimicrobial agents for XDROs based on known or anticipated resistance mechanisms
- Develop and integrate strategies for effective empiric coverage of patients with HABP/VABP who are at risk for XDROs
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.5 AMA PRA Category l Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.5 contact hours (.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-216-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.